Amicus Therapeutics (FOLD) Stock
Healthcare sector company. Here's the price, business snapshot, and what's worth knowing about Amicus Therapeutics in October 2026.
Amicus Therapeutics (ticker FOLD) is a biopharmaceutical company focused on treatments for rare genetic diseases, notably Fabry disease. Its oral pharmacological chaperone, migalastat (marketed as Galafold), is approved in multiple regions and underpins current commercial revenue, while Amicus advances a pipeline that includes gene therapy and next‑generation small‑molecule programmes. Investors should note the blend of commercial execution (market uptake, reimbursement) and ongoing clinical and regulatory risk from trials and filings. Biotech stocks can be volatile around trial readouts, approvals, or partnership news, and valuation often reflects pipeline potential as much as current sales. With a market capitalisation around $2.61bn, Amicus sits between commercial and growth‑stage biotech. This is general educational information, not personalised advice; values can rise and fall and returns are not guaranteed, so consider your risk tolerance and conduct further research before investing.
Amicus Therapeutics (FOLD) Stock Forecast
Analyst price target, next 12 months
$15.63
+7.8% vs today's $14.50
Price range over the last 12 months
Close to its 12-month high
Analysts covering Amicus Therapeutics have a consensus 12-month target of $15.63, above the current price of $14.50.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Amicus Therapeutics' stock with a target price of $15.63, indicating potential growth.
Financial Health
Amicus Therapeutics has strong revenue and cash flow, indicating solid financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Specialist rare‑disease play
Amicus targets niche, high‑value patient populations where clinical impact can justify premium pricing, though market uptake and reimbursement remain uncertain.
Commercial + clinical mix
Galafold provides a commercial base while ongoing trials and regulatory milestones drive future value; clinical setbacks could have a big effect.
Pipeline and partnerships
Gene‑therapy work and potential collaborations can de‑risk programmes or accelerate reach, but such deals and outcomes are uncertain and may dilute investors.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
